Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis

Journal of the National Cancer Institute

Volumn 97, Issue 24, 2005, Pages 1808-1815

  McCabe, Anthony ^a   Dolled Filhart, Marisa ^a   Camp, Robert L ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROTEIN ANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOMATION; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; CONFIDENCE INTERVALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 29844434293     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji427     Document Type: Article

References (21)

1. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002;117:723-8.
2. von Wasielewski R, Mengel M, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 2002;118:675-82.
3. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancen Breast Cancer Res Treat 1998;52:79-98.
4. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
5. Wan WH, Fortuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 1987;103:121-9.
6. Gancberg D, Di Leo A, Rouas G, Jarvinen T, Verhest A, Isola J, et al. Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol 2002;55:315-7.
7. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
8. Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A. The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol 2004;122:51-60.
9. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
10. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, et al. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004; 100:2084-92.
11. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer Cancer Res 2003;63:1101-5.
12. Petti LM, Reddy V, Smith SO, DiMaio D. Identification of amino acids in the transmembrane and juxtamembrane domains of the platelet-derived growth factor receptor required for productive interaction with the bovine papillomavirus E5 protein. J Virol 1997;71:7318-27.
13. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new-bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
14. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445-8.
15. Koscielny S, Terrier P, Spielmann M, Delarue JC. Prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer Inst 1998;90:712.
16. Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, et al. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 1999;18:6050-62.
17. Koscielny S, Terrier P, Daver A, Wafflart J, Goussard J, Ricolleau G, et al. Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. Eur J Cancer 1998;34:476-81.
18. Nathanson DR, Nash GM, Chen B, Gerald W, Paty PB. Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique. J Am Coll Surg 2003; 197:419-25.
19. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 1992;89:5321-5.
20. Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg MC, et al. Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J Mol Diagn 2003;5:184-90.
21. Riese DJ 2nd, van Raaij TM, Plowman GD, Andrew-s GC, Stern DF. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 1995;15:5770-6.